Dr. Anath Shalev, renowned diabetes researcher and Chief Scientific Officer of TIXiMED, Inc., a company dedicated to the development and commercialization of TXNIP inhibiting medications, presented her work on verapamil and TXNIP inhibition at the 2023 Immunology of Diabetes Society Congress in Paris.BIRMINGHAM, Ala.